PPCI In STEMI: What's New?

• Main Authors: I Gde Rurus Suryawan, -, Christian Pramudita B, -
• Format: Book Section PeerReviewed
• Language: English; English
• Published: Departement-SMF Penyakit Kardiologi dan Kedokteran Vaskular RSUD Dr. Soetomo Surabaya 2018
• Subjects: R Medicine (General); RC Internal medicine
• Online Access: https://repository.unair.ac.id/112495/1/Artikel%20PPCI%20In%20Stemi%20Whats%20New_compressed.pdf; https://repository.unair.ac.id/112495/2/PPCI%20In%20STEMI%20Whats%20New.pdf; https://repository.unair.ac.id/112495/
• Institution: Universitas Airlangga

Worldwide, ischaemic heart disease is the single most common cause of death and its frequency is increasing. However, in Europe, there (has been an overall trend for a reduction in ischaemic heart disease (mortality over the past three decades. Ischaemic heart disease disease now (accounts for almost 1.8 million annual deaths, or 20% of all deaths in Europe, although with large variationsbetween countries. The optimal management of patients found to have multivessel disease while undergoing primary percutaneous coronary intervention (P-PCI) for ST-segment elevation myocardial infarction is uncertain. In comparison with conservative management (medical treatment without reperfusion therapy), fibrinolytic therapy leads to improved left ventricular systolic function and survival in patients with myocardial infarction associated with either ST-segment elevation of left bundle-branch block. However, fibrinolytic therapy has several limitations. First, among those presenting with myocardial infarction with ST-segment elevation, some patients have a contraindication to fibrinolysis. Second, in approximately 15% of patients given fibrinolytic therapy, reperfusion does not occur. Third, about a quarter of those receiving fibrinolytic therapy have reocclusion of the infarct-related artery within 3 months after the myocardial infarction, with a resultant reinfarction. These limitations are minimized with the use of primary PCI.